According to Zacks, “Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. “
Several other research firms have also commented on EOLS. Stifel Nicolaus set a $33.00 price target on Evolus and gave the stock a buy rating in a research report on Wednesday, July 31st. JMP Securities dropped their price target on Evolus from $35.00 to $30.00 and set a market outperform rating for the company in a research report on Tuesday, August 13th. They noted that the move was a valuation call. Mizuho reiterated a buy rating and issued a $30.00 price target on shares of Evolus in a research report on Thursday, September 5th. Wells Fargo & Co assumed coverage on Evolus in a research report on Friday, June 28th. They issued a market perform rating and a $16.00 price target for the company. Finally, ValuEngine lowered Evolus from a buy rating to a hold rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $26.67.
Evolus (NASDAQ:EOLS) last issued its quarterly earnings data on Monday, August 12th. The company reported ($1.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.96) by ($0.41). The firm had revenue of $2.30 million during the quarter, compared to analysts’ expectations of $0.29 million. On average, research analysts predict that Evolus will post -4.28 earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in the business. BlackRock Inc. boosted its position in shares of Evolus by 12.2% during the second quarter. BlackRock Inc. now owns 994,396 shares of the company’s stock valued at $14,540,000 after buying an additional 107,946 shares during the period. Vanguard Group Inc. boosted its position in shares of Evolus by 46.3% during the second quarter. Vanguard Group Inc. now owns 710,230 shares of the company’s stock valued at $10,384,000 after buying an additional 224,758 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of Evolus during the second quarter valued at approximately $4,167,000. Wafra Inc. boosted its position in shares of Evolus by 106.2% during the second quarter. Wafra Inc. now owns 203,263 shares of the company’s stock valued at $2,972,000 after buying an additional 104,706 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Evolus by 4.2% during the second quarter. Northern Trust Corp now owns 164,574 shares of the company’s stock valued at $2,406,000 after buying an additional 6,575 shares during the period. Institutional investors and hedge funds own 19.20% of the company’s stock.
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Further Reading: Investing in Blue-Chip Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.